-
A New Milestone in Blood Cancer Treatment: FDA Expands Approval for Jaypirca
NYSE: $LLY A New Therapeutic Option for CLL/SLL Patients The landscape of blood cancer treatment has taken a significant step forward. The U.S. Food and Drug Administration (FDA) has granted expanded approval for Jaypirca (pirtobrutinib), marking it as the first and only non-covalent BTK inhibitor available for patients with previously untreated chronic lymphocytic leukemia (CLL)…
-
CaseBioscience® sa pripája k tímu, ktorý získal grant od ARPA-H vo výške až 7,3 milióna dolárov na podporu bunkových terapií pri izbovej teplote
FORT COLLINS, Colorado, 2. október 2026 /PRNewswire/ – Spolo?nos? CaseBioscience® dnes oznámila svoju ú?as? v multidisciplinárnom tíme pod vedením spolo?nosti Likarda, ktorému Agentúra pre pokro?ilé výskumné projekty v oblasti zdravia (ARPA-H) udelila prostredníctvom programu… Source: Read More
-
GMP Labeling Celebrates 40 Years of US Manufacturing for Regulated Industries
GRANITE BAY, Calif., Oct. 1, 2026 /PRNewswire/ — As pharmaceutical and biotechnology sectors navigate evolving global supply chain risks, GMP Labeling Inc. is utilizing Manufacturing Day 2026 to highlight its nearly 40-year history as a domestic manufacturer of critical compliance… Source: Read More
-
Revolutionizing Cell Therapy: CaseBioScience Joins $7.3M ARPA-H Project for Ambient Preservation
A Breakthrough in Medical Logistics The landscape of modern medicine is shifting, and CaseBioScience is at the forefront of a major advancement. The company has officially joined a multidisciplinary team that has been awarded up to $7.3 million in funding by the Advanced Research Projects Agency for Health (ARPA-H). This significant investment aims to solve…
-
B. Braun Medical Launches Introcan Safety® 2 Deep Access IV Catheter
New longer-length IV catheter, designed to increase catheter dwell time, offers fully automatic, passive needlestick protection and multi-access blood control BETHLEHEM, Pa., Oct. 1, 2026 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain… Source: Read More
-
Sinocare Unveils Integrated Chronic Disease Management Solutions at EASD 2024
Innovation at the Heart of Chronic Care At this year’s EASD (European Association for the Study of Diabetes) annual meeting, Sinocare took center stage to showcase its latest advancements in integrated chronic disease management. As global healthcare shifts toward more patient-centric models, Sinocare is positioning itself as a leader in digital health transformation. Integrated Solutions…
-
Sinocare Unveils Advanced Chronic Disease Management Solutions at EASD 2024
Revolutionizing Chronic Care Management At the recent EASD (European Association for the Study of Diabetes) 2024 Annual Meeting, global healthcare innovator Sinocare took center stage to showcase its latest advancements in chronic disease management. The company presented a comprehensive suite of integrated solutions designed to help patients and healthcare providers better manage diabetes and related…
-
CollPlant Biotechnologies Reports Q2 2026 Financial Results and Strategic Progress
NASDAQ: $CLGN Overview of Q2 2026 Financial Performance CollPlant Biotechnologies has officially released its financial results for the second quarter ending June 30, 2026, alongside a comprehensive corporate update. The company continues to advance its mission of transforming regenerative medicine through its proprietary plant-derived recombinant human collagen (rhCollagen) technology. Key Financial Highlights During the second…
-
A Breakthrough for Circadian Rhythm: Vanda Pharmaceuticals Reports Positive Phase III Results
New Hope for Delayed Sleep-Wake Phase Disorder Vanda Pharmaceuticals has reached a significant milestone in sleep medicine. The company recently announced positive results from its Phase III clinical trial evaluating Hetlioz (tasimelteon) for the treatment of Delayed Sleep-Wake Phase Disorder (DSWPD). Understanding DSWPD Delayed Sleep-Wake Phase Disorder is a chronic circadian rhythm disorder characterized by…
-
Airway Therapeutics Secures $1.9 Million NIH Grant to Advance Zelpultide Alfa Research
A Major Milestone for Neonatal Care Airway Therapeutics, a biopharmaceutical company dedicated to developing innovative treatments for respiratory diseases, has reached a significant milestone. The company has been awarded a $1.9 million grant from the National Institutes of Health (NIH) to support the progression of its clinical research. The Focus: Combating Bronchopulmonary Dysplasia (BPD) The…
-
Cytrellis Expands Global Reach: Ellacor Micro-Coring Technology Headed to South Korea
A New Chapter in Aesthetic Innovation Cytrellis, a leader in the development of groundbreaking aesthetic technologies, has officially announced a new strategic partnership to bring its flagship Ellacor micro-coring technology to the South Korean market. This move marks a significant milestone in the company’s mission to provide advanced, non-surgical solutions for skin rejuvenation globally. Understanding…
-
Revolutionizing Healthcare: How Open Source AI is Transforming Medical Video Analysis
A New Era for Medical Imaging The landscape of healthcare technology is shifting rapidly, thanks to a breakthrough in open-source artificial intelligence. A recent development has introduced a powerful new model designed specifically to accelerate global progress in medical video AI. By making this technology accessible, researchers and developers are now better equipped to handle…
-
Stepping Into the Future: CovationBio Unveils Bio-Based Sports Insoles
Innovation Meets Performance The materials industry is taking a major step toward sustainability. CovationBio has announced the debut of its groundbreaking sports insole, marking a significant milestone as the first non-food, bio-based sports insole to hit the market. This innovation will be officially showcased at the upcoming NW Materials Show. Why This Matters for the…
-
Typewriter Therapeutics Emerges from Stealth with $56 Million to Pioneer In Vivo CAR-T Medicines
A New Era for Cell Therapy The landscape of oncology treatment is shifting. Typewriter Therapeutics has officially emerged from stealth mode, announcing a significant $56 million Series A financing round. This milestone marks a bold step forward in the development of in vivo CAR-T medicines, aiming to make advanced cell therapies more accessible and effective.…
-
Shoulder Innovations Set to Present at Morgan Stanley 24th Annual Healthcare Conference
NYSE: $SI Strategic Participation in Healthcare Industry Leadership Shoulder Innovations, a company dedicated to advancing the field of shoulder replacement technology, has officially announced its participation in the prestigious Morgan Stanley 24th Annual Healthcare Conference. This event serves as a significant platform for industry leaders, investors, and innovators to discuss the future of medical technology.…
-
Mark Your Calendars: Research Solutions Sets Q4 and Fiscal Year 2026 Earnings Date
NASDAQ: $RSSS Upcoming Financial Reporting Research Solutions, Inc. (NASDAQ: RSSS) has officially announced that it will release its financial results for the fourth quarter and fiscal year ended June 30, 2026. Investors and stakeholders should mark their calendars for the morning of Wednesday, September 9, 2026, when the company plans to share its performance metrics.…
-
Genomma Lab Internacional Secures Strategic Long-Term Debt Financing
Strengthening Financial Foundations Genomma Lab Internacional, a prominent player in the pharmaceutical and personal care industry, has officially announced the completion of a significant long-term debt transaction. This strategic financial maneuver is designed to bolster the company’s capital structure and support its ongoing operational objectives. Key Details of the Transaction The company has utilized this…
-
Navigating the Future of Preclinical Oncology: Choosing the Right Xenograft Model
Advancing Cancer Research Through Model Selection In the rapidly evolving field of oncology drug discovery, selecting the appropriate preclinical model is more than a technical decision—it is a critical step that determines the translational success of a therapeutic candidate. A recent release highlights the vital importance of standardization and strategic selection across the diverse landscape…
-
The Future of Medicine: Why the Oligonucleotide CDMO Market is Poised for Massive Growth
A New Era in Therapeutic Innovation The pharmaceutical landscape is shifting rapidly, and at the heart of this transformation is the rise of oligonucleotide therapeutics. According to a recent report by MarketsandMarkets, the global oligonucleotide CDMO market is projected to reach a valuation of $11.14 billion by 2031, growing at a significant CAGR during the…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 08-30-2026 TO 09-05-2026
I’m excited to announce the release of my latest FREE bio tech stock catalyst report for the upcoming week. This new FREE stock report highlights bio tech companies that have an important upcoming event and an expected price move of 20 percent up or down ($ +/- 20%) to help you make informed market decisions.…
-
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NASDAQ: $NKTR SAN FRANCISCO, Aug. 28, 2026 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar’s Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common… Source: Read More
-
Aardvark Therapeutics Shareholders: Understanding the Recent Securities Class Action Notice
What You Need to Know About the Aardvark Therapeutics Lawsuit Investors who purchased shares of Aardvark Therapeutics, Inc. (NASDAQ: AARD) recently may be eligible to participate in a securities fraud class action lawsuit. A formal notice has been issued advising shareholders who suffered financial losses to consider their legal options regarding potential lead plaintiff roles.…
-
Un avance histórico: El NICE recomienda la financiación del sistema VitaSmart del NHS
Una victoria clave para el trasplante de órganos en el Reino Unido El Instituto Nacional para la Excelencia en Salud y Atención (NICE) del Reino Unido ha emitido una recomendación histórica a favor de la financiación por parte del NHS para el sistema VitaSmart, desarrollado por la compañía Bridge to Life. Esta decisión marca un…
-
Evonik Bolsters Global Biotech Footprint with New Vancouver GMP Facility
A Major Leap for Lipid-Based Drug Delivery Evonik has officially strengthened its position in the pharmaceutical manufacturing sector with the expansion of its lipid-based drug delivery capabilities. The company has announced the establishment of a new Good Manufacturing Practice (GMP) facility located in Vancouver, Canada, marking a significant milestone in their strategy to support the…